LONDON, UK / ACCESSWIRE / January 10, 2018 / Active-Investors has a free review on AbbVie Inc. (NYSE: ABBV) following the Company's announcement that it will begin trading ex-dividend on January 11, 2018. To capture the dividend payout, investors must purchase the stock a day prior to the ex-dividend date that is by latest at the end of the trading session on January 10, 2018. Active-Investors has initiated due-diligence on this dividend stock. Register with us for more free research including the one on ABBV:

www.active-investors.com/registration-sg/?symbol=ABBV

If your portfolio includes dividend stocks, you have come to the right place for timely information. All you need to do is sign up for your free membership at:

www.active-investors.com/registration-sg

Dividend Declared

On October 27, 2017, AbbVie's Board of Directors raised the Company's quarterly cash dividend by 11% from $0.64 per share to $0.71 per share. The cash dividend is payable February 15, 2018, to shareholders of record at the close of business on January 12, 2018.

AbbVie's indicated dividend represents a yield of 2.81%, which is more than four times the average dividend yield of 0.61% for the Healthcare sector. Since the Company's inception in 2013, AbbVie has increased its dividend by more than 77%. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

Dividend Insight

AbbVie has a dividend payout ratio of 51.2%, which denotes that the Company spends approximately $0.51 for dividend distribution out of every $1.00 earned. The dividend payout ratio reflects how much amount a company is returning to shareholders versus how much money it is keeping on hand to reinvest in growth, to pay off debt, and/or to add to its cash reserves.

According to analysts' estimates, AbbVie is forecasted to report earnings of $6.51 per share for the next year, which is more than double the Company's annualized dividend of $2.84 per share.

As of September 30, 2017, AbbVie's cash and cash equivalents totaled $8.45 billion compared to $5.10 billion as on December 31, 2016. For the nine months ended September 30, 2017, the Company's cash flow from operating activities totaled $7.38 billion compared to operating cash flow of $5.50 billion for the year ago same period. The Company's strong financial position indicates its ability to absorb any fluctuations in earnings and cash flow and to sustain the dividend distribution for a long period.

Recent Development for AbbVie

On December 20, 2017, AbbVie announced positive top-line results from the Phase-3 SELECT-MONOTHERAPY clinical trial. This ongoing study evaluated upadacitinib, an investigational oral JAK1-selective inhibitor, as a monotherapy treatment in patients with moderate to severe rheumatoid arthritis (RA) who did not adequately respond to treatment with methotrexate. Results showed that after 14 weeks of treatment, both once-daily doses of upadacitinib (15 mg and 30 mg) met the study's primary endpoints of ACR20 and low disease activity (LDA) versus continuing prior stable methotrexate therapy. Both doses also achieved all ranked and all key secondary endpoints.

Rheumatoid arthritis, which affects an estimated 23.7 million people worldwide, is a chronic and debilitating disease. Methotrexate is commonly used as a first-line therapy in rheumatoid arthritis, but many patients do not respond to or cannot tolerate methotrexate, which puts them at risk for disease progression.

About AbbVie Inc.

AbbVie is a global, research-driven biopharmaceutical Company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The Company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology, and neuroscience.

Stock Performance Snapshot

January 09, 2018 - At Tuesday's closing bell, AbbVie's stock was marginally up 0.75%, ending the trading session at $100.24.

Volume traded for the day: 4.04 million shares.

Stock performance in the last month ? up 6.37%; previous three-month period ? up 10.42%; past twelve-month period ? up 56.11%; and year-to-date ? up 3.65%

After yesterday's close, AbbVie's market cap was at $160.08 billion.

Price to Earnings (P/E) ratio was at 24.35.

The stock has a dividend yield of 2.83%.

The stock is part of the Healthcare sector, categorized under the Drug Manufacturers - Major industry. This sector was up 0.9% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors